TG Therapeutics

TG THERAPEUTICS INC

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

biotech lab

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

TGTX

TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

Crude,Oil,Pump,Jack,At,Oilfield,On,Sunset,Backround.,Fossil

Equities

Eurozone

Intraday Update

Markets

BCRX

GPUS

IART

PTCT

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Technicals

TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher.

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

TG Therapeutics Inc

Press Releases

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

ADMA Biologics

Akero Therapeutics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Vaxcyte

PTC Therapeutics

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

JP Morgan

Goldman Sachs

TD Cowen

B. Riley Securities

Comments

TG Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell